William Watremez

William Watremez

Auto-generated profile, based on publicly available information

William Watremez

Manchester Pharmacy School, University of Manchester, Manchester M13 9PT, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
MDMichael Daniels
Michael Daniels
JRJack Rivers-Auty
Jack Rivers-Auty
TSTom Schilling
Tom Schilling
NSNicholas G. Spencer
Nicholas G. Spencer
WWWilliam Watremez
William Watremez
DBDavid Brough
David Brough
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase-1 (COX-1) and COX-2 enzymes. The NLRP3 inflammasome is a multi-protein complex responsible for the processing of the proinflammatory cytokine interleukin-1β and is implicated in many inflammatory diseases. Here we show that several clinically approved and widely used NSAIDs of the fenamate class are effective and selective inhibitors of the NLRP3 inflammasome via inhibition of the volume-regulated anion channel in macrophages, independently of COX enzymes. Flufenamic acid and mefenamic acid are efficacious in NLRP3-dependent rodent models of inflammation in air pouch and peritoneum. We also show therapeutic effects of fenamates using a model of amyloid beta induced memory loss and a transgenic mouse model of Alzheimer’s disease. These data suggest that fenamate NSAIDs could be repurposed as NLRP3 inflammasome inhibitors and Alzheimer’s disease therapeutics.